Investment Rating - The investment rating for the company is "Outperform the Market" [5][3][29] Core Views - The company's revenue has shown a quarter-on-quarter increase, with rapid growth in new molecular business. The overall revenue for 2024 is 39.241 billion yuan, a decrease of 2.7%, but a 5.2% increase when excluding COVID-19 commercialization projects. The net profit attributable to the parent company is 9.450 billion yuan, down 1.6%, while the adjusted Non-IFRS net profit is 10.58 billion yuan, down 2.5% [6][3][5] - The CRDMO business model is driving growth, with revenue from chemical, testing, and biological services at 29.052 billion yuan (-0.4%, with an 11.2% increase excluding COVID-19 projects), 5.671 billion yuan (-13.3%), and 2.544 billion yuan (-0.3%) respectively [16][5] Summary by Sections Financial Performance - In Q4 2024, the company achieved a single-quarter revenue of 11.539 billion yuan (+6.9%) and a net profit of 2.917 billion yuan (+90.6%). The adjusted Non-IFRS net profit for the same quarter was 3.240 billion yuan (+20.4%) [6][3][5] - The gross profit margin for 2024 is 41.48% (+0.3pp), and the net profit margin is 24.38% (+0.3pp) [11][5] Business Segments - The small molecule CRO/CDMO business has shown strong growth, with over 460,000 new compounds synthesized and delivered in 2024 (+10%). The small molecule D&M business generated revenue of 17.87 billion yuan, with a 6.4% increase when excluding specific commercialization projects [23][5] - The TIDES business has also experienced rapid growth, achieving revenue of 5.80 billion yuan (+70.1%) and a 103.9% increase in orders on hand by the end of 2024 [23][5] Future Outlook - The company maintains a solid industry position, with steady quarterly performance improvements expected. The profit forecasts for 2025-2027 are adjusted upwards, with net profits projected at 11.162 billion yuan, 12.732 billion yuan, and 14.506 billion yuan respectively, reflecting year-on-year growth rates of 18.11%, 14.07%, and 13.93% [3][5][4]

Core Viewpoint - WuXi Biologics (02269) reported strong financial performance for 2024, achieving revenue of RMB 18.68 billion, with non-COVID revenue growing by 13.1% year-on-year, indicating robust growth potential and a need for valuation recovery [1][3][10] Financial Performance - The company achieved a gross profit of RMB 7.65 billion, a 12.1% increase year-on-year, and an EBITDA of RMB 6.55 billion, up 16.7% year-on-year [1] - The compound annual growth rate (CAGR) for non-COVID revenue from 2014 to 2024 is approximately 50% [1] - The stock price increased by 47.49% year-to-date as of March 25, 2024, but remains undervalued compared to estimates from major investment banks [1][10] Market Outlook - Major investment banks, including Morgan Stanley and CICC, have upgraded their forecasts for WuXi Biologics' revenue and net profit for 2025 and 2026, with target prices set at HKD 45 and HKD 50 respectively [1] - The global CXO industry is facing challenges, with many leading companies lowering their performance guidance for 2024, yet WuXi Biologics has successfully met its performance targets [2][3] Project Growth - WuXi Biologics achieved a record total of 817 integrated projects in 2024, with 151 new projects signed, exceeding the previous expectation of 110 [4][5] - The company has a strong pipeline with 402 preclinical projects, 328 early-stage clinical projects, and 87 late-stage clinical and commercial production projects, showing significant year-on-year growth [5] Strategic Advantages - The company’s dual-factory strategy and advanced technology platforms, such as WuXiBodyTM and WuXiUITM, are expected to enhance production efficiency and reduce costs significantly [6][8] - WuXi Biologics has maintained a 100% success rate in BLA submissions, reflecting its reliable quality management system [7][8] Valuation Potential - Despite strong fundamentals, WuXi Biologics' current PE ratio of 39.56 is significantly below its five-year average of 98.85, indicating substantial upside potential [10][12] - The company’s stock buyback program, with USD 4 billion completed out of a planned USD 6 billion, has increased its net asset value per share to HKD 10.75, enhancing investment attractiveness [9]